Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, interfering with DNA synthesis and function. Tipiracil hydrochloride inhibits thymidine phosphorylase, preventing trifluridine degradation and increasing its systemic exposure.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Metastatic colorectal cancer (m CRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.,Metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of therapy including a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
35 mg/m² orally twice daily on days 1-5 and 8-12 of each 28-day cycle. Maximum dose: 80 mg per dose.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
The terminal elimination half-life of trifluridine is approximately 1.4 to 2.1 hours. For tipiracil, the half-life is about 2.1 to 3.3 hours. The short half-lives necessitate twice-daily dosing to maintain therapeutic concentrations.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Trifluridine is primarily metabolized by thymidine phosphorylase to 5-(trifluoromethyl)uracil (inactive). Tipiracil is metabolized mainly via hepatic carboxylesterases and aldehyde oxidase, not significantly via CYP enzymes.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Trifluridine is primarily eliminated via metabolism and renal excretion. Approximately 29% of the trifluride dose is recovered in urine as trifluridine and its metabolites, with less than 3% as unchanged drug. Fecal excretion accounts for about 38% of the dose, mainly as metabolites. Tipiracil is predominantly excreted renally (about 55% as unchanged drug and metabolites) and fecally (about 19%).
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Trifluridine: <1% bound to plasma proteins. Tipiracil: about 8% bound to plasma proteins.
Approximately 20–30% bound to plasma proteins.
Trifluridine: Vd/F is approximately 0.4 ± 0.1 L/kg, indicating distribution into total body water. Tipiracil: Vd/F is about 0.3 ± 0.1 L/kg.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Following oral administration of the combination tablet, trifluridine has an absolute bioavailability of approximately 57% (fasted). Tipiracil bioavailability is about 70% (fasted). Food may alter absorption.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
For GFR 30-59 m L/min: reduce dose to 20 mg/m² twice daily. For GFR 15-29 m L/min: reduce dose to 15 mg/m² twice daily. Contraindicated if GFR <15 m L/min.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 25 mg/m² twice daily. Child-Pugh C: not recommended.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Not established. Safety and efficacy in pediatric patients have not been studied.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended; monitor renal function and adjust based on renal impairment. Elderly patients may have increased risk of myelosuppression and infections.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: NEUTROPENIA/THROMBOCYTOPENIA; AND GASTROINTESTINAL TOXICITY Neutropenia/Thrombocytopenia: Severe and life-threatening neutropenia and thrombocytopenia can occur. Obtain complete blood counts prior to each cycle and as clinically indicated. Withhold, reduce, or discontinue dosing for severe neutropenia or thrombocytopenia. Gastrointestinal Toxicity: Severe gastrointestinal toxicity including diarrhea, nausea, vomiting, and abdominal pain can occur. Withhold, reduce, or discontinue dosing for severe gastrointestinal toxicity.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Bone Marrow Suppression: May cause severe neutropenia, thrombocytopenia, and anemia. Monitor blood counts.,Gastrointestinal Toxicity: Severe diarrhea, nausea, vomiting, abdominal pain, and stomatitis. Manage with supportive care.,Renal Toxicity: Proteinuria, nephrotic syndrome. Monitor renal function.,Hepatic Toxicity: Elevations of liver enzymes and bilirubin. Monitor liver function.,Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of effective contraception and avoid breastfeeding.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
None reported in prescribing information. Use caution in patients with severe renal impairment (Cr Cl <30 m L/min) or severe hepatic impairment.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Take within 1 hour after a meal (breakfast and dinner) to reduce variability and improve tolerability. Avoid grapefruit or grapefruit juice? No established interaction; however, general caution due to potential CYP3A4 involvement? (minimal). High-fat meals may reduce peak concentration but do not significantly alter overall exposure; timing with meals is recommended not for efficacy but to mitigate gastrointestinal side effects.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Trifluridine/tipiracil is embryotoxic and teratogenic in animal studies. In humans, avoid use during pregnancy; effective contraception required during treatment and for at least 6 months after last dose. First trimester: highest risk of major malformations; second and third trimesters: risk of fetal growth restriction and adverse neonatal outcomes.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
No human data on excretion in breast milk. Based on drug properties, likely present; advise against breastfeeding during treatment and for at least 1 day after last dose. M/P ratio unknown.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No established dose adjustments for pregnancy; avoid use. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may alter exposure, but no data to guide adjustment.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Tipiracil hydrochloride/trifluridine (Lonsurf) is a combination oral cytotoxic agent used for refractory metastatic colorectal cancer and gastric cancer. Trifluridine incorporates into DNA, inhibiting thymidylate synthase; tipiracil inhibits trifluridine degradation by thymidine phosphorylase. Administer within 1 hour after morning and evening meals to reduce variation in exposure. Avoid severe neutropenia by monitoring CBCs before and after each cycle; hold for ANC <500/mm³ or febrile neutropenia. Use antiemetics as needed; nausea/vomiting occur in ~50% of patients. Dose reduction recommended for severe myelosuppression, including thrombocytopenia and anemia. No strong CYP interactions; avoid concurrent use of UGT1A1 or thymidine phosphorylase inhibitors? (limited data). Consider growth factor support for prolonged neutropenia.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Take each dose with a glass of water within 1 hour after breakfast and dinner; do not crush or chew tablets.,Swallow tablets whole; do not take if vomiting occurs after a dose—skip that dose and resume next scheduled dose.,Store at room temperature away from moisture and heat; keep bottle tightly closed.,Common side effects include nausea, vomiting, diarrhea, loss of appetite, fatigue, and low blood cell counts.,Contact healthcare provider immediately if fever, signs of infection (sore throat, cough), unusual bleeding/bruising, or severe tiredness occur.,Use effective contraception during treatment and for at least 6 months after the last dose for females and 3 months for males.,Avoid handling crushed or broken tablets; if contact occurs, wash skin thoroughly.,Do not breastfeed during treatment and for at least 1 day after last dose.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
"Tipiracil, a component of the combination chemotherapeutic agent Lonsurf (with trifluridine), inhibits thymidine phosphorylase and can also inhibit organic cation transporter 2 (OCT2). Pramipexole, a dopamine agonist used for Parkinson's disease and restless legs syndrome, is primarily eliminated renally via active tubular secretion mediated by OCT2. When coadministered, Tipiracil reduces the renal clearance of Pramipexole by inhibiting OCT2, leading to increased plasma concentrations of Pramipexole. This elevates the risk of dose-dependent adverse effects such as orthostatic hypotension, hallucinations, somnolence, and impulse control disorders."
"Tipiracil inhibits thymidine phosphorylase, which is involved in the metabolism of prazosin, leading to reduced clearance and increased systemic exposure of prazosin. This can result in enhanced alpha-adrenergic blockade, causing profound hypotension, dizziness, and syncope, especially during initial dosing or dose escalation."
"The serum concentration of Histamine can be increased when it is combined with Tipiracil."
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE vs CLADRIBINE, answered by our medical review team.
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE is a Antineoplastic Agent that works by Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, interfering with DNA synthesis and function. Tipiracil hydrochloride inhibits thymidine phosphorylase, preventing trifluridine degradation and increasing its systemic exposure.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE is: 35 mg/m² orally twice daily on days 1-5 and 8-12 of each 28-day cycle. Maximum dose: 80 mg per dose.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE is classified as Category C. Trifluridine/tipiracil is embryotoxic and teratogenic in animal studies. In humans, avoid use during pregnancy; effective contraception required during treatment and for at least 6. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.